Apr 1992: Joined Nippon Life Insurance Company Apr 2002: Established JBS Co., Ltd.; Representative Director, President Jul 2007: Representative Director, President, Future Brain Co., Ltd. (current) Jan 2014: Joined the Company Jul 2014: Executive Officer; General Manager, Business Support Division and Head of Business Strategy Department Apr 2016: General Manager, President's Office Jun 2018: Director; in charge of Reliability Assurance, Corporate Planning, and Medical Affairs Jun 2019: Director; in charge of Business Strategy and Administration Apr 2020: General Manager, Sales Division Jun 2020: Managing Director; in charge of Sales Jun 2021: Senior Managing Director; in charge of Sales and Administration Apr 2023: In charge of Sales Jun 2024: Director, Senior Managing Executive Officer Apr 2026: Representative Director, Chairman of the Board (current)

Apr 2003: Joined the Company Apr 2016: General Manager, Corporate Planning Division (Research) Oct 2017: Frontier Research Unit Leader and General Manager, Corporate Planning Division (Research) Apr 2018: General Manager, Research Planning Division Jun 2018: Executive Officer Jun 2020: Director; in charge of Research and Development; General Manager, Research Division and Director, Drug Discovery Research Institute Jun 2021: Managing Director; in charge of Research and Business Strategy; General Manager, Research Division Oct 2022: Representative Director, President, AlliedCel Co., Ltd. Apr 2023: In charge of Research Jun 2024: Director, Senior Managing Executive Officer Apr 2026: Representative Director, President, Chief Scientific Officer (current)

Jun 1994: Consultant Pediatrician, Princess Alexandra Hospital, Saint Jamue Hospital, and Pedro de Elizalde Children's Hospital Mar 2003: Research Physician, Hammersmith Medicines Research Nov 2004: Global Medical Director, Takeda Global R&D Jul 2009: Vice President R&D, Medicines Development Leader Rare Disease, Rare Diseases Business Unit, GlaxoSmithKline Sep 2015: Established Andrea Spezzi Executive Consultant (current) Jan 2016: Co-founder and Chief Medical Officer, Orchard Therapeutics Jun 2021: Independent Outside Director, Bloomsbury Genetic Therapies (current) Sep 2021: Co-Founder, President and CEO / Board Executive Director, Rejuvitas Inc. Sep 2023: Advisor and Partner (Acting), Discovery Ventures Healthcare Fund (current) Dec 2023: Development Strategy Advisor, the Company Jun 2024: Director, Managing Executive Officer; in charge of Development, the Company (current) Apr 2026: Director, Senior Managing Executive Officer (current)

Apr 1986: Joined Daiichi Pharmaceutical Co., Ltd. (now Daiichi Sankyo Company, Limited) Oct 1999: Seconded to PMD-VAC Co., Ltd.; General Manager, Regulatory Affairs Department Apr 2005: Chief Marketing Authorization Holder and General Manager, PMD-VAC Co., Ltd. Oct 2011: Returned from secondment; Head of R&D Group, Vaccine Business Planning, Daiichi Sankyo Company, Limited Jul 2012: Seconded to Japan Vaccine Co., Ltd.; Chief Marketing Authorization Holder and General Manager, Reliability Assurance Department Apr 2019: Joined the Company; Department Manager attached to Production Division Apr 2020: Chief Marketing Authorization Holder; General Manager, Safety Management Department and Head of Post-Marketing Surveillance Office, Reliability Assurance Division Sep 2020: General Manager, Corporate Planning Division (in charge of Vaccine Business); Department Manager attached to Safety Management Department Jun 2021: Director; in charge of Production and Reliability Assurance; General Manager, Production Division Mar 2024: Director, JCR Luxembourg S.A. (current) Apr 2024: In charge of Reliability Assurance; General Manager, Reliability Assurance Division and General Manager, Regulatory Affairs Department Jun 2024: Director, Managing Executive Officer; in charge of Reliability Assurance; General Manager, Reliability Assurance Division (current)

Apr 1968: Joined Daigo Eiyo Kagaku Co., Ltd. Sep 1975: Established the Company; Representative Director; President Jul 1993: Representative Director, JCR Co., Ltd. (now Future Brain Co., Ltd.) Jul 1995: Chairman, Jiexi Pharmaceutical Co., Ltd. (renamed Hebei Jiexi Biological Products Co., Ltd.) Jun 2005: Chairman of the Board and Chief Executive Officer (CEO) Jun 2007: President and Chief Operating Officer (COO) Nov 2015: Representative Director, President, JCR International S.A. Apr 2026: Director, Founder (current)

Apr 1974: Joined the National Police Agency Feb 1994: Chief, Kochi Prefectural Police Sep 1997: Director, Accounting Division, Secretariat of the National Police Agency Sep 2001: Chief Inspector, Secretariat of the National Police Agency Aug 2002: Chief, Kanagawa Prefectural Police Aug 2004: Deputy Commissioner General, Metropolitan Police Department Sep 2005: Grand Chamberlain, Imperial Household Agency Apr 2009: Ambassador Extraordinary and Plenipotentiary to Luxembourg Jun 2012: Retired from the same post Jun 2013: Outside Audit & Supervisory Board Member, Marubeni Corporation Jun 2015: Outside Director, Toutetsu Kogyo Co., Ltd. Jun 2016: Audit & Supervisory Board Member, the Company; Outside Audit & Supervisory Board Member, Keihin Electric Express Railway Co., Ltd. and Kanden Engineering Corporation (current) Jun 2017: Director, the Company (current) Jun 2018: Outside Audit & Supervisory Board Member, Aioi Nissay Dowa Insurance Co., Ltd. Jun 2025: Outside Director (Audit and Supervisory Committee Member), Keihin Electric Express Railway Co., Ltd. (current)

Apr 1988: Joined IBM Japan, Ltd. Oct 2003: Visiting Researcher, Research Center for Advanced Science and Technology, The University of Tokyo Apr 2007: Part-time Lecturer, Graduate School of Technology Management, Yamaguchi University; Visiting Researcher, National Graduate Institute for Policy Studies Mar 2011: Managing Director, Public Interest Incorporated Association 3.11 Orphans Culture and Sports Support Organization (current) Apr 2012: Specially Appointed Associate Professor, Graduate School of Technology Management, Yamaguchi University Jun 2015: Specially Appointed Professor, Graduate School of Technology Management, Yamaguchi University (current) Jan 2017: Director, Special Olympics Nippon Apr 2018: Visiting Joint Researcher, Graduate School of Frontier Sciences, The University of Tokyo Jun 2018: Director, the Company (current)

Apr 1970: Research Physician, First Department of Surgery, The University of Tokyo School of Medicine Apr 1982: Chief, Medical Office, First Department of Surgery, The University of Tokyo Jun 1988: Visiting Researcher, Department of Surgery, University of California, San Francisco Jul 1992: Lecturer, First Department of Surgery, The University of Tokyo Oct 1992: Professor, First Department of Surgery, Kyorin University School of Medicine Apr 2004: Dean, Kyorin University School of Medicine Apr 2010: President, Kyorin University Jun 2013: Outside Audit & Supervisory Board Member, Dainippon Sumitomo Pharma Co., Ltd. (now Sumitomo Pharma Co., Ltd.) Jun 2017: Outside Director, Sumitomo Pharma Co., Ltd. Apr 2018: Honorary President, Kyorin University (current) Jun 2018: Chairman, Japan Pancreas Foundation Apr 2019: Chairman, International Medical Research Foundation (current) Jun 2019: Outside Audit & Supervisory Board Member, Sanki Engineering Co., Ltd. (current) Jun 2022: Director, the Company (current) Jun 2023: Chairman, Ato Gakuen Educational Corporation (current); Chairman, Japan-China Medical Association Foundation (current) Aug 2023: Outside Director, Pasona Group Inc. Aug 2025: Outside Director (Audit and Supervisory Committee Member), Pasona Group Inc. (current)

Oct 1984: Joined Roussel Uclaf S.A. (France) (now Aventis) Sep 1996: Joined Sanofi S.A. (France) Jun 2001: Representative Director, President, Sanofi-Synthelabo K.K. (now Sanofi K.K.) May 2005: Representative Director, President, Sanofi-Aventis K.K. (now Sanofi K.K.) Jan 2010: Representative Director, President, GlaxoSmithKline K.K. Jun 2013: Outside Director, the Company Apr 2017: Chairman, GlaxoSmithKline K.K. Nov 2017: Resigned as Outside Director, the Company Feb 2019: Retired as Chairman, GlaxoSmithKline K.K. May 2019: Outside Director, Bonac Corporation Mar 2020: Outside Director, Noile-Immune Biotech Inc. (current) Sep 2020: Outside Director, Rezolute, Inc. (RZLT) (current) Jun 2022: Outside Director, LUCA Science Inc. (current) Jun 2022: Director, the Company (current)

Oct 2003: Executive Officer, Asahi Kasei Pharma Corporation Apr 2008: Director and Managing Executive Officer, Asahi Kasei Pharma Corporation Apr 2010: Representative Director, President and President Executive Officer, Asahi Kasei Pharma Corporation Apr 2011: Executive Officer, Asahi Kasei Corporation Apr 2014: President Executive Officer, Asahi Kasei Corporation Jun 2014: Representative Director, President, Asahi Kasei Corporation Apr 2016: Director, Asahi Kasei Corporation Jun 2017: Outside Director, Medipal Holdings Corporation (current) Jun 2019: Outside Director, Daicel Corporation (current) Jun 2019: Outside Director, Tokyo Century Corporation (current) Jan 2020: Special Advisor, the Company Jun 2021: Chairman, Japanese Foundation for Cancer Research (current) Jun 2024: Special Advisor, Asahi Kasei Corporation (current) Jun 2025: Chairman, Japan Bioindustry Association (current) Jun 2026: Director, the Company (current)

Oct 1999: Joined Glaxo Wellcome K.K.; Representative Director, Vice President Mar 2000: Representative Director, President, Glaxo Wellcome K.K. Jan 2001: Representative Director, President, GlaxoSmithKline K.K. Mar 2003: Corporate Executive Team Member, GlaxoSmithKline plc May 2008: Head of Pharmaceuticals Division (Asia Pacific and Japan), GlaxoSmithKline plc Jan 2010: Representative Director, Chairman, GlaxoSmithKline K.K. Feb 2010: Foundational Global Head, Rare Diseases, GlaxoSmithKline plc Jun 2010: Outside Director, the Company Apr 2013: Resigned as Outside Director, the Company Jun 2013: Joined AstraZeneca PLC as Executive Vice President, Global Portfolio & Product Strategy Nov 2013: Director, Chief Financial Officer, AstraZeneca PLC; Chairman, AstraZeneca K.K. (current) Jun 2018: Outside Director, Orchard Therapeutics PLC Aug 2021: Chief Executive Officer, Alexion AstraZeneca Rare Diseases (current); Chief Strategy Officer, AstraZeneca Group (current) Jun 2023: Outside Director, the Company (current) Dec 2023: Director, Selectis S.A. (current)

Apr 1985: Joined Nihon Kangyo Sumimaru Securities Co., Ltd. May 1989: Joined UBS Securities Jul 1996: Joined ING Barings Securities Dec 2000: Joined Lehman Brothers Securities Co., Ltd. Oct 2008: Managing Director, Barclays Capital Securities Ltd. Jun 2010: Director, Medipal Holdings Corporation Apr 2012: Managing Director, Medipal Holdings Corporation; in charge of IR; General Manager, Business Development Division and Business Development Department May 2016: Director, SPLine Co., Ltd.; Director, Mediet Co., Ltd. Jun 2016: Director, MEDICEO Co., Ltd. Feb 2018: Director, JCR USA, Inc. (current) Jun 2018: Senior Managing Director, Medipal Holdings Corporation (current); Director, the Company (current) Jun 2022: General Manager, Business Development Division, Medipal Holdings Corporation (current)

Mar 1992: Branch Manager, Utsunomiya Branch, Nippon Life Insurance Company Mar 1997: General Manager, Nihonbashi Regional Head Office, Nippon Life Insurance Company Mar 2001: General Manager, Metropolitan Agency Department No. 4, Nippon Life Insurance Company Jun 2002: Full-time Audit & Supervisory Board Member, Sohgo Security Services Co., Ltd. (now ALSOK Co., Ltd.) Apr 2009: Executive Officer, ALSOK Co., Ltd. Jun 2013: Audit & Supervisory Board Member, the Company (current)

Apr 1982: Joined Mitsubishi Kasei Corporation (now Mitsubishi Chemical Corporation) Jun 2009: Director, Executive Officer; General Manager, Product Strategy Division, Tanabe Mitsubishi Pharma Corporation Apr 2012: Director, Managing Executive Officer; General Manager, Development Division, Tanabe Mitsubishi Pharma Corporation Apr 2014: Representative Director, Senior Managing Executive Officer, Tanabe Mitsubishi Pharma Corporation Jun 2014: Representative Director, President, President Executive Officer, Tanabe Mitsubishi Pharma Corporation Apr 2020: Director, Tanabe Mitsubishi Pharma Corporation Jun 2020: Senior Advisor, Tanabe Mitsubishi Pharma Corporation Jul 2022: Advisor, Medipal Holdings Corporation Jun 2023: Outside Director, Sawai Group Holdings Co., Ltd. (current) Jun 2025: Audit & Supervisory Board Member, the Company (current); Outside Audit & Supervisory Board Member, Medipal Holdings Corporation (current)

Oct 2002: Appointed Public Prosecutor, Tokyo District Public Prosecutors Office Jul 2013: Compliance Office Manager, Innovation Network Corporation of Japan Jul 2016: Retired as Public Prosecutor Jul 2016: Registered as Attorney, Japan Federation of Bar Associations (Daiichi Tokyo Bar Association); Attorney, City-Yuwa Partners (current) Apr 2018: Councillor, Daiichi Tokyo Bar Association Apr 2020: Vice Chair, Gender Equality Committee, Kanto Federation of Bar Associations Jun 2021: Outside Director, Toutetsu Kogyo Co., Ltd. (current) Jun 2025: Audit & Supervisory Board Member, the Company (current); Outside Audit & Supervisory Board Member, GS Yuasa Corporation (current)